New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
09:31 EDTNYMXNymox completes enrollment for second BPH re-injection study
Nymox Pharmaceutical announced the closing of enrollment for Study NX02-0022, the company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate. The NX02-0022 study enrolled patients who had previously participated in an earlier NX-1207 BPH study, and in the new trial these men received a second open-label injection of NX-1207. The study used a new lyophilized formulation of NX-1207 that has longer stability stored at room temperature. An interim analysis of the new efficacy data from the NX02-0022 study will be reported within the next few weeks.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
10:05 EDTNYMXNymox reports Q3 EPS (2c) vs. (3c) last year
Reports Q3 revenue $81.1K vs. $88.9K.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use